

## **AMENDMENT TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings of claims in the application:

Claims 1-79 (Canceled)

80. (new) A sustained-release dosage form, comprising oxymorphone or a salt thereof, a hydrophilic polymer, a binder, and a diluent.

81. (new) The sustained-release dosage form of claim 80, wherein the dosage form contains granules having a diameter from about 0.1 mm to about 3 mm.

82. (new) The sustained-release dosage form of claim 80, further comprising an alkylcellulose.

83. (new) The sustained-release dosage form of claim 80, further comprising ethylcellulose.

84. (new) The sustained-release dosage form of claim 80, wherein the dosage form is in the form of a tablet.

85. (new) The sustained-release dosage form of claim 80, wherein the dosage form is in the form of a capsule.

86. (new) The sustained-release dosage form of claim 80, wherein the dosage form is in the form of a matrix.

87. (new) The sustained-release dosage form of claim 80, wherein the dosage form provides a therapeutic effect for about 12 hours or more.

88. (new) The sustained-release dosage form of claim 80, wherein the dosage form provides a therapeutic effect for about 24 hours or more.

89. (new) A sustained-release dosage form, made by the process comprising:

- (a) mixing oxymorphone or a salt thereof with a hydrophilic polymer, a binder, and a diluent;
- (b) subjecting the mixture to shear to form granules; and
- (c) incorporating the granules into a dosage form.

90. (new) The process of claim 89, wherein the granules have a diameter from about 0.1 mm to about 3 mm.

91. (new) The process of claim 89, wherein step (c) comprises incorporating the granules into a tablet.

92. (new) The process of claim 89, wherein step (c) comprises incorporating the granules into a capsule.

93. (new) The process of claim 89, wherein the dosage form is a matrix.
94. (new) The process of claim 89, wherein step (a) further comprises mixing oxymorphone or a salt thereof with an alkylcellulose.
95. (new) The process of claim 89, wherein step (a) further comprises mixing oxymorphone or a salt thereof with ethylcellulose.
96. (new) The process of claim 89, wherein the dosage form provides a therapeutic effect for about 12 hours or more.
97. (new) The process of claim 89, wherein the dosage form provides a therapeutic effect for about 24 hours or more.
98. (new) A process of making a sustained-release dosage form comprising:
- (a) mixing oxymorphone or a salt thereof with a hydrophilic polymer, a binder, and a diluent;
  - (b) subjecting the mixture to shear to form granules; and
  - (c) incorporating the granules into a dosage form.
99. (new) The process of claim 98, wherein the granules have a diameter from about 0.1 mm to about 3 mm.
100. (new) The process of claim 98, wherein step (c) comprises incorporating the granules into a tablet.
101. (new) The process of claim 98, wherein step (c) comprises incorporating the granules into a capsule.
102. (new) The process of claim 98, wherein the dosage form is a matrix.
103. (new) The process of claim 98, wherein step (a) further comprises mixing oxymorphone or a salt thereof with alkylcellulose.
104. (new) The process of claim 98, wherein step (a) further comprises mixing oxymorphone or a salt thereof with ethylcellulose.
105. (new) The process of claim 98, wherein the dosage form provides a therapeutic effect for about 12 hours or more.
106. (new) The process of claim 98, wherein the dosage form provides a therapeutic effect for about 24 hours or more.